详情页

当前位置：首页 > 详情页

Selinexor as a Therapeutic Target: Advances in Non-small Cell and Small Cell Lung Cancer Treatment Strategies

8| 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Department of Thoracic Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China. [2]Department of Hematology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.

出处：

DOI：

ISSN：

关键词： Selinexor lung cancer NSCLC SCLC XPO1 SINE

摘要：

Selinexor treats lung cancer, particularly non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). This review summarizes the prevalence and types of lung cancer and emphasizes the challenges associated with current treatments like resistance and limited effectiveness. Selinexor is a selective inhibitor of nuclear export (SINE) that has emerged as a potential therapy that targets the nuclear export of tumor suppressor proteins. The mechanisms of selinexor, its potential in combination therapies, and challenges like side effects and drug resistance are explained in this review. Key findings highlight the effectiveness of selinexor in preclinical studies, particularly against KRAS-mutant NSCLC and in combination with chemotherapy for SCLC. The review concludes with a discussion of future directions and underscores the potential of selinexor to improve the treatment strategies for lung cancer.Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

基金：

语种：

WOS：

PubmedID：

中科院分区：

出版当年[2025]版中科院分区表Review为是的期刊

：

大类 | 4 区医学

小类 | 4 区肿瘤学 4 区药学

最新[2025]版

：

大类 | 4 区医学

小类 | 4 区肿瘤学 4 区药学

JCR分区：

出版当年[2024]版：

Q1 PHARMACOLOGY & PHARMACY Q2 ONCOLOGY

最新[2024]版：

Q1 PHARMACOLOGY & PHARMACY Q2 ONCOLOGY

影响因子： 4.1 最新[2024版] 3.2 最新五年平均 4.1 出版当年[2025版] 3.2 出版当年五年平均 4.1 出版前一年[2024版]

第一作者：

第一作者机构： [1]Department of Thoracic Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.

通讯作者：

通讯机构： [1]Department of Thoracic Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China. [*1]Department of ThoracicSurgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang,China

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Characterization of MET exon 14 skipping in Chinese non-small cell lung cancer (NSCLC) patients. [2]Practice Patterns of Treatment Strategy of Limited-Stage Small-Cell Lung Cancer: Survey of Chinese Oncologists [3]Durvalumab Combined With Chemoradiotherapy for Limited Stage Small Cell Lung Cancer (Camel-01) [4]Alectinib in Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer as First-Line or Sequential Treatment in China [5]A Phase II Study of Perioperative Ivonescimab Alone or Combined with Chemotherapy in Resectable NonSmall Cell Lung Cancer [6]Case report: Emerging therapies for transformed small cell lung cancer: efficacy of serplulimab and a comprehensive case report [7]Small cell lung cancer (SCLC) incidence and trends vary by gender, geography, age, and subcategory based on population and hospital cancer registries in Hebei, China (2008-2017) [8]A Phase I/II Clinical Study of SAF-189s in Non-small Cell Lung Cancer (NSCLC) Patients [9]Exploring the utility of TP53 mutations as prognostic markers in patients with non-small cell lung cancer (NSCLC) [10]Analysis of Irradiated Induced Lung Injury in Non-Small Cell Lung Cancer (NSCLC) Treated by Three-Dimensional Conformal Radiotherapy(3DCRT)